Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early switch to dolutegravir/lamivudine versus continuation of INSTI-based triple therapy in virologically suppressed adults with HIV-1
2019-004241-32Phase 3Active
- Sponsor
- Società Italiana Malattie Infettive e Tropicali
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir + lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Società Italiana Malattie Infettive e Tropicali. Primary endpoint: Virological rebound at week 48. Started May 2021; status: active.
02
Drugs
dolutegravir + lamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-004241-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004241-32.